We prospectively enrolled in the study all men diagnosed with localized prostate cancer who accepted FT as an alternative of whole gland treatment (radical prostatectomy or external beam radiotherapy) or declined active surveillance protocol. Inclusion criteria were a histologically biopsy-proven PC, clinically stage ≤T2, age ≥45 years, ≥5 years of life expectancy, grading groups ≤3, and subtotal gland ablation. Exclusion criteria were non-adenocarcinoma histology, grading group ≥4, metastatic/nodal disease or extracapsular extension or seminal vesicle invasion at imaging, active rectal diseases, radio-recurrent PC, whole gland ablation, and hormonal treatment. Patients with lesions located out of the anterior-posterior distance of the device (>40 mm) were also excluded because an efficient treatment could not be achieved.